Recent Updates
Recently added Catalysts

Benazepril plus hydrochlorothiazide

Phase 3

Hypertension | Small molecule | Cardiovascular |Novartis AG|Last Updated: Jul 9, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment296
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00367094Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential HypertensionPHASE3 COMPLETED 296Jul 1, 2006 -Jul 9, 20071 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change in diastolic blood pressure from baseline to week 8
Secondary Endpoints
Change in systolic blood pressure from baseline to week 8
Proportion of patients with blood pressure less than 140/90 mmHg at week 8
Ambulant blood pressure monitoring profiles at baseline and week 8
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
Benazepril plus hydrochlorothiazideDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Male or female patients, age 18 or older * Given informed consent * Diagnosed as having mild to moderate essential hypertension Exclusion Criteria: * Severe hypertension * Significant preexisting cardiovascular and cerebrovascular disease * Diabetes mellitus type 1 or poorly...

Countries:China
Unlock Eligibility Criteria